Early trial combines two chemo drugs with radiation for aggressive sarcomas

NCT ID NCT04037527

Terminated Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This Phase 1 trial tested a combination of two chemotherapy drugs (gemcitabine and docetaxel) given alongside radiation therapy for adults with large (over 5 cm), high-grade soft tissue sarcoma of the arms or legs. The goal was to find the safest dose and see how well the body tolerates the treatment. Only 9 people took part before the study was stopped early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gemcitabine and docetaxel (chemotherapy drugs) plus radiation therapy
What this could lead to: If it works, this could point toward a way to shrink large, high-grade sarcomas before surgery using a combination of chemo and radiation.
What could go wrong: This was a very early Phase 1 safety study with only 9 participants and was terminated early. The combination may cause significant side effects, and it is unknown if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.